Humanized anti-CLL-1 antibodies

Inventors

Jiang, Ying-Ping • Junutula, Jagath R. • Presta, Leonard G. • Tsurushita, Naoya

Assignees

Onk Therapeutics Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11072662-B2

Patent

Publication Date

2021-07-27

Expiration Date


Abstract

Provided herein are humanized antibodies specific for CLL-1.

Core Innovation

The invention provides an antibody that binds CLL-1, including a variable light chain comprising SEQ ID NO: 21 followed by further framework sequence SEQ ID NO: 22, and a variable heavy chain comprising SEQ ID NO: 23 followed by further framework sequence SEQ ID NO: 24. Humanized antibody repertoire variants are described as M26-derived and M31-derived variants with murine CDRs grafted onto human immunoglobulin frameworks, using defined SEQ ID-based variable light/heavy chain constructs.

The disclosed antibodies include defined human constant regions selected from IgG1, IgG2, IgG3, and IgG4, and include constant-region cysteine-substituted modification formats. The disclosed repertoire includes combinations of HuM26L4/HuM31VL variants with corresponding HuM31VH variants, and defined hinge-region and Fc format choices are described within the humanized framework context.

The disclosed antibody-related compositions further include conjugates and multi-specific formats in which CLL-1 binding is used for selective cytotoxicity. The document describes CDC and ADCC-enabled uses, as well as ADC and ADC conjugates using benzodiazepine-type cytotoxic payloads, and describes CAR constructs using CLL-1 binding domains. Selectivity is demonstrated as loss of effect in CLL-1 knockout and differential killing between quiescent and proliferating CLL-1+ cell conditions, including MDR+ve settings.

Claims Coverage

The independent claim is directed to a CLL-1-binding antibody defined by specific variable light-chain and variable heavy-chain sequence components, with multiple dependent claims refining the antibody’s constant region, format, and payload/conjugate features. The inventive features center on SEQ ID-defined variable light/heavy chain frameworks for CLL-1 binding, optional human constant-region selection and cysteine-substituted modification, and optional bi-specific targeting and benzodiazepine cytotoxic conjugation.

CLL-1-binding antibody with SEQ ID-defined variable light and variable heavy chains

An antibody that binds CLL-1, the antibody comprising a variable light chain comprising SEQ ID NO: 21 followed by further framework sequence SEQ ID NO: 22; and a variable heavy chain comprising SEQ ID NO: 23 followed by further framework sequence SEQ ID NO: 24.

Human constant region selected from IgG1 to IgG4

The antibody additionally comprises a human constant region selected from IgG1, IgG2, IgG3, and IgG4.

Constant region cysteine-substituted modification

The antibody is an antibody with a constant region cysteine-substituted modification.

Bi-specific antibody with a defined second target antigen set

A bi-specific antibody is provided that has a first arm binding CLL-1 and a second arm that binds a second target antigen selected from CD33, CD123, IL1Rap, GPR114, or CD3 on T cells.

scFv region-containing antibody format

The antibody includes an scFv region.

Benzodiazepine cytotoxic agent for the conjugate

The cytotoxic agent is a benzodiazepine.

Across the independent and dependent claim set provided, the core coverage is a CLL-1-binding antibody defined by SEQ ID NO:21/22 (variable light) and SEQ ID NO:23/24 (variable heavy), with further coverage for specified human constant-region classes, cysteine-substituted constant-region modifications, optional scFv formatting and bi-specific second-target selection, and conjugates that use a benzodiazepine cytotoxic agent.

Stated Advantages

Selective killing is described in connection with CLL-1-dependent cytotoxicity, including loss of effect in CLL-1 knockout cells and differential killing between quiescent and proliferating CLL-1+ cell conditions.

Activity is described in MDR+ve settings.

Documented Applications

CDC and ADCC uses enabled by a CLL-1 binding antibody.

ADC/antibody-drug conjugate conjugates using benzodiazepine-type cytotoxic payloads for CLL-1-dependent cytotoxicity, including MDR+ve settings.

CAR constructs using CLL-1 binding domains.

Bi-specific antibodies having a first arm binding CLL-1 and a second arm binding a second target antigen selected from CD33, CD123, IL1Rap, GPR114, or CD3 on T cells.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.